Inari Medical Inc is driven by a strong corporate philosophy and a set of core values that define its mission and operations. The company represents a commitment to innovation, patient-centric care, and continuous improvement in the field of medical devices. Inari Medical Inc firmly believes in transforming the lives of patients through its cutting-edge technologies, such as the FlowTriever and ClotTriever systems. With a focus on delivering safe and effective solutions for the treatment of venous and arterial diseases, Inari Medical Inc strives to enhance patient outcomes and provide healthcare professionals with reliable tools. By embracing a patient-first approach and fostering a culture of collaboration and excellence, Inari Medical Inc sets a high standard in the industry.

Inari Medical Inc is primarily present in the United States.

Inari Medical Inc has achieved several significant milestones since its inception. The company successfully went public in May 2020, listing its shares on the NASDAQ stock exchange under the ticker symbol "NARI". Inari Medical has also developed groundbreaking medical devices, including the FlowTriever and ClotTriever Systems, which offer minimally invasive solutions for the treatment of blood clots. These innovative products have received regulatory approvals and have been adopted by physicians worldwide. In addition, Inari Medical continues to experience rapid growth and expansion, establishing itself as a leader in the field of venous thromboembolism treatment.

Inari Medical Inc, founded in 2011, is a leading provider of solutions for the treatment of venous diseases. The company specializes in developing innovative medical devices, particularly for treating blood clots and other vascular conditions. Inari's flagship product, the ClotTriever System, is a minimally invasive device used by physicians to remove clots from blocked vessels, providing a non-surgical alternative to traditional treatments. Inari Medical Inc has experienced significant growth since its inception, driven by the increasing demand for its cutting-edge technologies and a strong focus on improving patient outcomes. With their commitment to revolutionizing venous therapy, Inari Medical Inc continues to drive advancements in the field of vascular intervention.

The main competitors of Inari Medical Inc in the market include companies such as Penumbra Inc, Medtronic Plc, and AngioDynamics Inc.

Inari Medical Inc is primarily active in the healthcare industry.

Inari Medical Inc is a medical device company with a unique business model. The company specializes in developing and commercializing innovative devices for the treatment of venous diseases, specifically deep vein thrombosis (DVT) and pulmonary embolism (PE). Inari Medical Inc's proprietary technologies and products aim to improve patient outcomes by providing minimally invasive solutions for the removal of blood clots. With a focus on research, development, and commercialization of cutting-edge medical devices, Inari Medical Inc aims to revolutionize the treatment of venous diseases and contribute to the improvement of patient care worldwide.

KGV Inari Medical iznosi −53,77.

Koeficijent cijene i prometa Inari Medical iznosi 3,86.

AlleAktien Qualitätsscore za Inari Medical je 2/10.

Promet očekivana Inari Medical iznosi 612,19 mil. USD.

Dobit očekivana Inari Medical iznosi −43,93 mil. USD.

Inari Medical Inc. is one of the leading companies in the field of medical technology, focusing on the development and marketing of devices and products for the treatment of vascular and thromboembolic diseases. The business model of Inari Medical is based on the development and marketing of innovative products and services tailored to the needs of patients and physicians. The company operates in two main areas: venous diseases and pulmonary embolism. In the field of venous diseases, Inari Medical offers the ClotTriever System, a unique device for removing blood clots from the deep veins of the body. This system is a non-invasive alternative to traditional surgery, allowing for a minimally invasive procedure. It is a revolutionary procedure that offers benefits such as faster recovery time and high success rate. In the field of pulmonary embolism, Inari Medical has developed the FlowTriever System to remove blood clots from the pulmonary arteries. This system has proven to be effective and offers similar benefits to the ClotTriever System. Both systems are FDA approved and sold worldwide. Inari Medical has also developed a wide range of accessories and consumables to support these devices and improve treatment outcomes. In addition, Inari Medical also offers comprehensive training and education programs for physicians and medical personnel to ensure the safe and effective application of the systems. Inari Medical also has a strong patent portfolio, which has helped to increase its growth and success in the medical industry. The company has obtained several patents for its products and technologies and plans to further expand its portfolio through continuous research and development. Overall, the business model of Inari Medical Inc. has shown that the demand for innovative and effective solutions for the treatment of vascular and thromboembolic diseases is high. Through its reliable products and services, the company has solidified its position as a leading provider of medical technology in the market.

Inari Medical isplaćuje dividendu od 0 USD raspoređenu preko isplata godišnje.

Dividenda za Inari Medical trenutno se ne može izračunati ili tvrtka ne isplaćuje dividendu.

ISIN od Inari Medical je US45332Y1091.

WKN od Inari Medical je A2P41U.

Oznaka burze tvrtke Inari Medical je NARI.

U posljednjih 12 mjeseci Inari Medical je isplatio dividendu u iznosu od . To odgovara prinosu dividende od oko . Za sljedećih 12 mjeseci Inari Medical će vjerojatno isplatiti dividendu u iznosu od 0 USD.

Trenutni prinos dividende od Inari Medical iznosi .

Inari Medical isplaćuje dividende kvartalno. One se isplaćuju u mjesecima .

Inari Medical je isplatio dividendu svake godine u posljednjih 0 godina.

Za nadolazećih 12 mjeseci očekuje se isplata dividendi u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Inari Medical se pripisuje sektoru 'Zdravlje'.

Da bi primili posljednju dividendu od Inari Medical od 04. 10. 2024. u iznosu od 0 USD, trebali ste imati dionicu u portfelju prije Ex-dana 04. 10. 2024..

Posljednja isplata dividende izvršena je 04. 10. 2024..

U godini 2023 su od Inari Medical 0 USD isplaćene kao dividende.

Dividende od Inari Medical isplaćuju se u USD.